Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction

Urology

Volumn 60, Issue 2 SUPPL. 2, 2002, Pages 4-11

  Corbin, Jackie D ^a   Francis, Sharron H ^a   Webb, David J ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; CYCLIC GMP; ERYTHROMYCIN; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; ISOENZYME; KETOCONAZOLE; MILRINONE; MORPHINE; NARCOTIC ANALGESIC AGENT; NITRIC OXIDE; NIZATIDINE; PETHIDINE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V; RANITIDINE; RITONAVIR; SAQUINAVIR; SILDENAFIL; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; CORPUS CAVERNOSUM; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG TARGETING; DYSPEPSIA; ENZYME INHIBITION; ERECTILE DYSFUNCTION; FLUSHING; HEADACHE; HUMAN; NOSE CONGESTION; PHOTOTRANSDUCTION; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; TREATMENT OUTCOME; VALIDATION PROCESS; VASCULAR SMOOTH MUSCLE; VISUAL DISORDER;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; CYCLIC GMP; HUMANS; IMPOTENCE; MALE; NITRIC OXIDE; PENILE ERECTION; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PIPERAZINES; VASODILATOR AGENTS;

EID: 0036755003     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)01686-2     Document Type: Article

References (48)

1. McDonald L.J., Murad F. Nitric oxide and cyclic GMP signaling. Proc Soc Exp Biol Med. 211:1996;1-6.
2. Lucas K.A., Pitari G.M., Kazerounian S., et al. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev. 52:2000;375-414.
3. Ebrey T., Koutalos Y. Vertebrate photoreceptors. Prog Retin Eye Res. 20:2001;49-94.
4. Corbin J.D., Francis S.H. Cyclic GMP phosphodiesterase-5 target of sildenafil. J Biol Chem. 274:1999;13729-13732.
5. Ignarro L.J. Nitric oxide a unique endogenous signaling molecule in vascular biology. Biosci Rep. 19:1999;51-71.
6. Lue T.F. Erectile dysfunction. N Engl J Med. 342:2000;1802-1813.
7. Burnett A.L. Role of nitric oxide in the physiology of erection. Biol Reprod. 52:1995;485-489.
8. Ignarro L.J., Bush P.A., Buga G.M., et al. Nitric oxide and cyclic GMP formation upon electrical stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun. 170:1990;843-850.
9. Foster D.C., Wedel B.J., Robinson S.W., et al. Mechanisms of regulation and functions of guanylyl cyclases. Rev Physiol Biochem Pharmacol. 135:1999;1-39.
10. Chuang A.T., Strauss J.D., Steers W.D., et al. cGMP mediates corpus cavernosum smooth muscle relaxation with altered cross-bridge function. Life Sci. 63:1998;185-194.
11. Baxendale R.W., Smith E.J., Stanley M., et al. Selectivity of sildenafil citrate and other phosphodiesterase type 5 (PDE5) inhibitors against human phosphodiesterase types 7-11. [abstract] J Clin Pharmacol. 41:2001;1015.
12. Francis S.H., Turko I.V., Corbin J.D. Cyclic nucleotide phosphodiesterases relating structure and function. Prog Nucleic Acid Res Mol Biol. 65:2001;1-52.
13. Beavo J.A. Cyclic nucleotide phosphodiesterases functional implications of multiple isoforms. Physiol Rev. 75:1995;725-748.
14. Wallis R.M., Corbin J.D., Francis S.H., et al. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol. 83:(suppl 5A):1999;3C-12C.
15. Gopal V.K., Francis S.H., Corbin J.D. Allosteric sites of phosphodiesterase-5 (PDE5). A potential role in negative feedback regulation of cGMP signaling in corpus cavernosum. Eur J Biochem. 268:2001;3304-3312.
16. Boolell M., Allen M.J., Ballard S.A., et al. Sildenafil an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res. 8:1996;47-52.
17. Ballard S.A., Gingell C.J., Tang K., et al. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol. 159:1998;2164-2171.
18. Sugiyama A., Satoh Y., Shiina H., et al. Cardiac electrophysiologic and hemodynamic effects of sildenafil, a PDE5 inhibitor, in anesthetized dogs. J Cardiovasc Pharmacol. 38:2001;940-946.
19. Stief C.G., Uckert S., Becker A.J., et al. Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue. Urology. 55:2000;146-150.
20. Senzaki H., Smith C.J., Juang G.J., et al. Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure. FASEB J. 15:2001;1718-1726.
21. Moreland R.B., Goldstein I., Traish A. Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells. Life Sci. 62:1998;309-318.
22. Saenz de Tejada I., Angulo J., Cuevas P., et al. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res. 13:2001;282-290.
23. Kim N.N., Huang Y.H., Goldstein I., et al. Inhibition of cyclic GMP hydrolysis in human corpus cavernosum smooth muscle cells by vardenafil, a novel, selective phosphodiesterase type 5 inhibitor. Life Sci. 69:2001;2249-2256.
24. Lipsy R.J., Fennerty B., Fagan T.C. Clinical review of histamine2 receptor antagonists. Arch Intern Med. 150:1990;745-751.
25. Physicians' Desk Reference. 56th ed. 2002;1311-1312 Medical Economics Company, Inc, Montvale, NJ.
26. Wallis R.M., Casey J., Howe L., et al. Characterisation of retinal phosphodiesterase (PDE) isozymes and the effects of sildenafil in vitro. [abstract] Ophthalmic Res. 30:(suppl 1):1998;111.
27. Corbin J.D., Turko I.V., Beasley A., et al. Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities. Eur J Biochem. 267:2000;2760-2767.
28. Walker D.K., Ackland M.J., James G.C., et al. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica. 29:1999;297-310.
29. Purvis K., Muirhead G.J., Harness J.A. The effects of sildenafil on human sperm function in healthy volunteers. Br J Clin Pharmacol. 53:2002;53S-60S.
30. Goldstein I., Lue T.F., Padma-Nathan H., et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 338:1998;1397-1404.
31. Webb D.J., Freestone S., Allen M.J., et al. Sildenafil citrate and blood-pressure-lowering drugs results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol. 83:(suppl 5A):1999;21C-28C.
32. Webb D.J., Muirhead G.J., Wulff M., et al. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J Am Coll Cardiol. 36:2000;25-31.
33. Cheitlin M.D., Hutter A.M., Brindis R.G., et al. Use of sildenafil (Viagra) in patients with cardiovascular disease. Circulation. 99:1999;168-177.
34. Viagra (sildenafil citrate) prescribing information. 1999;Pfizer Inc, New York, NY.
35. Jackson G., Benjamin N., Jackson N., et al. Effects of sildenafil citrate on human hemodynamics. Am J Cardiol. 83:(suppl 5A):1999;13C-20C.
36. Morales A., Gingell C., Collins M., et al. Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction. Int J Impot Res. 10:1998;69-74.
37. Laties A.M., Fraunfelder F.T. Ocular safety of Viagra (sildenafil citrate). Trans Am Ophthal Soc. 97:1999;115-125.
38. Milligan P.A., Marshall S.F., Karlsson M.O. A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction. Br J Clin Pharmacol. 53:2002;45S-52S.
39. Nichols D.J., Muirhead G.J., Harness J.A. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects absolute bioavailability, food effects, and dose proportionality. Br J Clin Pharmacol. 53:2002;5S-12S.
40. Muirhead G.J., Allen M.J., James G.C., et al. Pharmacokinetics of sildenafil (VIAGRA), a selective cGMP PDE5 inhibitor, after single oral doses in fasted and fed healthy volunteers. [abstract] Br J Clin Pharmacol. 42:1996;268P.
41. Hyland R., Roe E.G., Jones B.C., et al. Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. Br J Clin Pharmacol. 51:2001;239-248.
42. Muirhead G.J., Faulkner S., Harness J.A., et al. The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers. Br J Clin Pharmacol. 53:2002;37S-43S.
43. Wilner K., Laboy L., LeBel M. The effects of cimetidine and antacid on the pharmacokinetic profile of sildenafil citrate in healthy male volunteers. Br J Clin Pharmacol. 53:2002;31S-36S.
44. Zusman R.M., Morales A., Glasser D.B., et al. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol. 83:(suppl 5A):1999;35C-44C.
45. Muirhead G.J., Wulff M.B., Fielding A., et al. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br J Clin Pharmacol. 50:2000;99-107.
46. Muirhead G., Wilner K., Colburn W., et al. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil citrate. Br J Clin Pharmacol. 53:2002;21S-30S.
47. Eardley I., Ellis P., Boolell M., et al. Onset and duration of action of sildenafil for the treatment of erectile dysfunction. Br J Clin Pharmacol. 53:2002;61S-65S.
48. Laties A., Ellis P., Mollon J.D. The effects of sildenafil citrate (VIAGRA) on color discrimination in volunteers and patients with erectile dysfunction. [abstract] Invest Ophthalmol Vis Sci. 40:(4 suppl):1999;S693.